NEVVI Medicare utilization intelligence

← back

Provider profile

SADIQ, AHAD M.D

Hematology-Oncology · NPI 1861525560 · FORT WAYNE, IN

1
Groups
44
Codes · 2024
54,450
Disclosed services

SADIQ, AHAD is a Hematology-Oncology in FORT WAYNE, IN, a member of 1 medical group, who billed 44 distinct codes to Medicare Part B in 2024.

Groups: AMERICAN ONCOLOGY PARTNERS PA (FORT WAYNE, IN)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

54,450
disclosed services
44
codes billed to Medicare Part B
Prior year · CY2023 47,399 disclosed services

This provider's disclosed Medicare payments across all codes were premium in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) premiumpremium premiumpremium
J1453 Injection, fosaprepitant, 1 mg premiumpremium premiumpremium
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj premiumpremium premiumpremium
J9271 Injection, pembrolizumab, 1 mg premiumpremium premiumpremium
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml premiumpremium premiumpremium
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg premiumpremium premiumpremium
J1100 Injection, dexamethasone sodium phosphate, 1 mg premiumpremium premiumpremium
J2469 Injection, palonosetron hcl, 25 mcg premiumpremium premiumpremium
J0897 Injection, denosumab, 1 mg premiumpremium premiumpremium
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more premiumpremium premiumpremium
J9190 Injection, fluorouracil, 500 mg premiumpremium premiumpremium
96375 Injection of additional new drug or substance into vein premiumpremium premiumpremium
J3475 Injection, magnesium sulfate, per 500 mg premiumpremium premiumpremium
J3480 Injection, potassium chloride, per 2 meq premiumpremium premiumpremium
96413 Administration of chemotherapy into vein, 1 hour or less premiumpremium premiumpremium
J2405 Injection, ondansetron hydrochloride, per 1 mg premiumpremium premiumpremium
J9045 Injection, carboplatin, 50 mg premiumpremium premiumpremium
Q5122 Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg premiumpremium premiumpremium
96372 Injection of drug or substance under skin or into muscle premiumpremium premiumpremium
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less premiumpremium premiumpremium
96415 Administration of chemotherapy into vein, each additional hour premiumpremium premiumpremium
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more premiumpremium premiumpremium
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less premiumpremium premiumpremium
96417 Administration of additional new drug or substance into vein, 1 hour or less premiumpremium premiumpremium
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour premiumpremium premiumpremium
J1200 Injection, diphenhydramine hcl, up to 50 mg premiumpremium premiumpremium
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries premiumpremium premiumpremium
78815 Nuclear medicine study from skull base to mid-thigh with ct scan premiumpremium premiumpremium
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l premiumpremium premiumpremium
96361 Infusion into a vein for hydration, each additional hour premiumpremium premiumpremium
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle premiumpremium premiumpremium
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg premiumpremium premiumpremium
J7030 Infusion, normal saline solution , 1000 cc premiumpremium premiumpremium
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion premiumpremium premiumpremium
71260 Ct scan of chest with contrast premiumpremium premiumpremium
J3490 Unclassified drugs premiumpremium premiumpremium
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more premiumpremium premiumpremium
71250 Ct scan of chest without contrast premiumpremium premiumpremium
74177 Ct scan of abdomen and pelvis with contrast premiumpremium premiumpremium
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more premiumpremium premiumpremium
96360 Infusion into a vein for hydration, 31-60 minutes premiumpremium premiumpremium
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle premiumpremium premiumpremium
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more premiumpremium premiumpremium
96374 Injection of drug or substance into vein premiumpremium premiumpremium

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.